Brief: Royalty Pharma Announces Research And Development Funding Collaboration For Chronic Immune-Mediated Diseases
30/03/2026 14:20
March 30 (Reuters) - Royalty Pharma PLC RPRX.O: ROYALTY PHARMA ANNOUNCES RESEARCH AND DEVELOPMENT FUNDING COLLABORATION FOR CHRONIC IMMUNE-MEDIATED DISEASES ROYALTY PHARMA - ANNOUNCES $500 MILLION RESEARCH AND DEVELOPMENT CO-FUNDING AGREEMENT WITH JOHNSON & JOHNSON FOR 2026-2027 ROYALTY PHARMA - AGREEMENT TO ADVANCE DEVELOPMENT OF JNJ-4804 FOR AUTOIMMUNE DISEASES Source text: ID:nGNX7wjM4q Further company coverage: RPRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Royalty Pharma
See all newsAnalysis: Revolution Medicines' Europe efforts signal solo launch ambitions for cancer drug
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
Royalty Pharma falls after Novartis' cholesterol drug fails in study
Brief: Royalty Pharma Announces Update On Novartis’ Phase 3 Topline Results For Pelacarsen
Teva's immune disorder drug meets main goal in mid-stage trial (updated)